fabrazyme 5 mg
sanofi - aventis israel ltd - agalsidase beta 5 mg/ml - powder for concentrate for infusion - agalsidase beta - long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease.
fabrazyme 5mg powder for concentrate solution for i.v. infusion
zuellig pharma corp - agalsidase beta - powder for concentrate solution for i.v. infusion - 5mg
fabrazyme 35mg powder for concentrate solution for iv infusion
zuellig pharma corp - agalsidase beta - powder for concentrate solution for iv infusion - 35mg
fabrazyme 5 mg powder for concentrate solution for i.v. infusion
genzyme corp - usa; importer: sanofi-aventis philippines, inc. - agalsidase beta - powder for concentrate solution for i.v. infusion - 5 mg
fabrazyme 35 mg powder for concentrate for solution for infusion (iv)
n/a; importer: sanofi-aventis philippines, inc.; distributor: n/a - agalsidase beta - powder for concentrate for solution for infusion (iv) - 35 mg
fabrazyme 5 mg powder for concentrate for solution for infusion
genzyme europe b.v., netherlands - agalsidase beta - powder for concentrate for solution for infusion - 5 mg/ml
fabrazyme 35 mg powder for concentrate for solution for infusion
genzyme europe b.v., netherlands - agalsidase beta - powder for concentrate for solution for infusion - 5 mg/ml
fabrazyme
genzyme australasia pty ltd - agalsidase beta -
fabrazyme
genzyme australasia pty ltd - agalsidase beta -
fabrazyme 5mg injection
sanofi-aventis (malaysia) sdn. bhd. - recombinant human alfa galactosidase (r-hagal) -